Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone sustained-release tablets for moderate to severe cancer pain in opioid-tolerant patients
ChiCTR2400090327Phase 4Not yet recruiting
- Sponsor
- Quzhou People's Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxycodone in cancer pain, sponsored by Quzhou People's Hospital. Primary endpoints: Adverse reaction incidence rate and Effective rate of analgesia. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
oxycodone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2400090327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090327.